Effect of IVIG administration on complement activation and HLA antibody levels: ORIGINAL ARTICLE

Transplant International

Volumn 23, Issue 10, 2010, Pages 1015-1022

  MacHimoto, Takafumi ^a   Guerra, Giselle ^b   Burke, George ^b   Fricker, Frederick Jay ^a   Colona, Jane ^b   Ruiz, Phillip ^b   Meier Kriesche, Herwig Ulf ^a   Scornik, Juan ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

complement; HLA antibodies; intravenous immunoglobulin

Indexed keywords

COMPLEMENT COMPONENT C3B; HLA ANTIBODY; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DESENSITIZATION; FLOW CYTOMETRY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; KIDNEY GRAFT REJECTION; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES; COMPLEMENT ACTIVATION; COMPLEMENT C3B; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 77956326085     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01088.x     Document Type: Article

References (14)

1. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower sensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004 15 : 3256.
2. Stegall MD, Gloor J, Winters JL, Moore SB, DeGoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific antibody. Am J Transplant 2006 6 : 346.
3. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIG/anti-CD20 versus high dose IVIG in the treatment of antibody-mediated rejection. Am J Transplant 2009 5 : 1099.
4. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001 345 : 747.
5. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in aguinea pig model. J Clin Invest 1989 84 : 1974.
6. Fischer MB, Ma M, Goerg S, et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 1996 157 : 549.
7. Dempsey PW, Allison MED, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996 271 : 348.
8. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992 62 : S82.
9. Watanabe J, Scornik JC. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 2005 5 : 2786.
10. Opelz G, Susal C. A positive crossmatch and treatment with IVIG. Am J Transplant 2005 5 : 2601.
11. Nielsen CH, Marquart HV, Prodinger WM, Leslie RG. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes. Immunology 2001 104 : 418.
12. Ishida H, Omoto K, Shimizu T, et al. Usefulness of splenectomy for chronic active antibody-mediated rejection after renal transplantation. Transpl Int 2008 21 : 602.
13. Jordan SC, Vo AA, Peng A, et al. Intravenous Gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006 6 : 459.
14. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008 359 : 242.